Sanofi reports sales growth amid Dupixent's China launch, but reveals PDUFA delay in Pompe disease program

Sanofi released its first quarter earnings report Wednesday, and while the company saw positive news regarding growth and sales — particularly in China — they also revealed for the first time a delay in one of their lead Phase III programs.